Atlas Trials

Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma

Clinical trial NCT02141542 · COMPLETED

Trial details

NCT number
NCT02141542
Sponsor
F. Stephen Hodi, MD
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Metastatic Melanoma
Start date
2014-05-01
Primary completion
2020-09-23
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.